An interventional study of PROTECT-HER KIT (Protection Motivation Theory-Based HPV Screening Education Kit) and Standard Ministry of Health (MOH) Educational Materials in Cervical Cancer Screening and Human Papillomavirus Infection, sponsored by Universiti Teknologi Mara. Not yet recruiting at 1 site in Malaysia. Open to female participants aged 30 Years to 65 Years, including healthy volunteers. Per ClinicalTrials.gov, last updated 2026-11-17.
Sponsored by Universiti Teknologi Mara · Not applicable, Interventional, and Screening
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
This study aims to evaluate the effectiveness of the Protection Motivation Theory-Based HPV Screening Education Kit (PROTECT-HER KIT) in improving human papillomavirus (HPV) self-sampling uptake among eligible women in KOSPEN communities in Selangor, Malaysia. The study uses a two-arm, parallel cluster randomised controlled trial involving 106 women aged 30-65 years across eight KOSPEN localities. Localities will be randomly allocated to receive either the PROTECT-HER KIT educational intervention or standard Ministry of Health educational materials. The primary outcome is HPV self-sampling uptake assessed at one and two months following the intervention. Secondary outcomes include cervical cancer awareness and protection motivation measured at baseline, one month, and two months.
The goal of this cluster randomised controlled trial is to evaluate the effectiveness of the Protection Motivation Theory-Based HPV Screening Education Kit (PROTECT-HER KIT) in improving human papillomavirus (HPV) self-sampling uptake, cervical cancer awareness, and protection motivation among eligible women in the Komuniti Sihat Pembina Negara (KOSPEN) communities in Selangor, Malaysia. The PROTECT-HER KIT is a newly developed health education package designed to improve women's knowledge, perceived risk, confidence, and motivation to undergo HPV self-sampling for cervical cancer screening.
The main questions this study aims to answer are:
Will the PROTECT-HER KIT increase HPV self-sampling uptake among eligible women in KOSPEN communities in Selangor?
Will the PROTECT-HER KIT improve cervical cancer awareness among participants?
Will the PROTECT-HER KIT improve protection motivation, including perceived severity, perceived vulnerability, response efficacy, self-efficacy, and perceived response costs related to HPV self-sampling?
To evaluate the effectiveness of the PROTECT-HER KIT, researchers will conduct a two-arm cluster randomised controlled trial involving eight KOSPEN localities in Selangor. The localities will be randomly assigned to either the intervention group or the control group. The intervention group will receive the PROTECT-HER KIT, comprising a structured face-to-face health education session using flipcharts, video demonstrations, facilitated discussions, and practical guidance on HPV self-sampling, followed by WhatsApp reinforcement messages and action-planning reminders. The control group will receive standard cervical cancer prevention educational materials from the Ministry of Health Malaysia.
Participants will:
Complete a baseline questionnaire (T0) assessing their sociodemographic characteristics, cervical cancer awareness, protection motivation, and previous cervical cancer screening history.
Receive either the PROTECT-HER KIT educational intervention or standard Ministry of Health educational materials, depending on the KOSPEN locality to which they belong.
Complete follow-up questionnaires at approximately one month (T1) and two months (T2) after the educational intervention to assess changes in cervical cancer awareness, protection motivation, and HPV self-sampling uptake.
Report whether they have undergone HPV self-sampling for cervical cancer screening during the follow-up period.
The findings will help determine whether a theory-based, community-delivered health education intervention can improve HPV self-sampling uptake and support cervical cancer prevention efforts in Malaysia.
580 studies on the registry are indexed under Papillomavirus Infections; 133 are open to participants now.
This study's planned enrollment of 106 is below the median of 229 across 404 interventional studies indexed under Papillomavirus Infections.
Browse Papillomavirus Infections studies →Universiti Teknologi Mara is the lead sponsor of 27 studies on the registry; 9 are open to participants now.
Counted across the registry records on this site, refreshed daily.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Informed consent
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Participants will receive a structured, approximately 90-minute face-to-face educational session incorporating four modules: cervical cancer and HPV risk education, HPV self-sampling procedures and skills, emotional and practical barriers, and action planning. Educational materials include flipcharts, video demonstrations, facilitated discussions and standardised WhatsApp reinforcement and reminders.
Behavioral: PROTECT-HER KIT (Protection Motivation Theory-Based HPV Screening Education Kit)
Participants will receive a one-off distribution of existing Ministry of Health educational materials containing general information on women's health and cervical cancer prevention. Participants will continue to have access to routine cervical cancer screening services.
Behavioral: Standard Ministry of Health (MOH) Educational Materials
Participants allocated to the intervention group will receive the PROTECT-HER KIT, a structured educational intervention based on Protection Motivation Theory (PMT) to improve cervical cancer awareness, protection motivation, and HPV self-sampling uptake. The intervention consists of a single approximately 90-minute, face-to-face small-group educational session delivered by the principal researcher using flipcharts, a video demonstration, facilitated discussions, and practical guidance on HPV self-sampling. The educational content addresses perceived severity, perceived vulnerability, response efficacy, self-efficacy, and perceived response costs related to cervical cancer screening. Standardised WhatsApp reinforcement messages and action-planning reminders will be provided following the session to encourage HPV self-sampling uptake. The intervention will be delivered after completion of the baseline assessment (T0).
Participants allocated to the control group will receive a one-off distribution of standard health educational materials sourced from the Ministry of Health Malaysia. These materials provide general information on women's health, cervical cancer prevention, and cervical cancer screening. Unlike the intervention group, participants will not receive the structured PROTECT-HER KIT educational session or standardised WhatsApp reinforcement messages. The educational materials will be distributed once following completion of the baseline assessment (T0). Participants will continue to have access to routine cervical cancer screening services.
Secondary: Cervical cancer awareness
Cervical Cancer Awareness Scale (Cx-CAS), 15 items
Time frame: Baseline, 1 and 2 months
Secondary: Cervical cancer awareness
Cervical Cancer Awareness Scale (Cx-CAS), 15 items
Time frame: Baseline, 1 and 2 months
Secondary: Protection motivation
Adapted Malay PMT questionnaire, 24 items
Time frame: Baseline, 1 and 2 months
Plan to share: No — Individual participant data (IPD) will not be made publicly available due to the sensitive nature of the information collected, including cervical cancer screening history, HPV self-sampling uptake, and health-related perceptions. Data confidentiality and participant privacy will be maintained in accordance with the approved study protocol, institutional ethical requirements, and applicable data protection regulations. Study findings will be disseminated through scientific publications and presentations in aggregate form without identifying individual participants.
No publications or documents are linked to this record.
Start is estimated for Mar 2027; primary completion for Jun 2027, 3 months later.
Of 108 non-industry interventional studies with no phase under Papillomavirus Infections, half reached primary completion within 26 months of starting (the median), counting those still running; a quarter within 11 and three quarters within 48. This study's planned 3 months is below that.
Counting every sponsor, half of 117 studies reached it within 26 months; a quarter within 11 and three quarters within 48.
How these figures are worked out, and which studies are left out of them.
From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗
This study is not yet recruiting, as verified in Nov 2026. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Universiti Teknologi Mara